Share on StockTwits
 

Pluristem Therapeutics (NASDAQ:PSTI) Director Israel Ben-Yoram sold 35,625 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $4.51, for a total value of $160,668.75. Following the sale, the director now directly owns 314,806 shares of the company’s stock, valued at approximately $1,419,775. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Separately, analysts at MLV Capital raised their price target on shares of Pluristem Therapeutics from $4.50 to $6.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock.

Shares of Pluristem Therapeutics (NASDAQ:PSTI) traded down 5.87% on Tuesday, hitting $4.17. 2,047,026 shares of the company’s stock traded hands. Pluristem Therapeutics has a 52 week low of $2.47 and a 52 week high of $4.54. The stock has a 50-day moving average of $3.59 and a 200-day moving average of $3.31. The company’s market cap is $249.7 million.

Pluristem Therapeutics Inc (NASDAQ:PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.